Bristol Myers Squibb’s experimental drug for Crohn’s disease, ozanimod, did not help patients achieve disease remission in a late-stage study. Crohn’s is a chronic bowel disease causing inflammation in the digestive tract, leading to symptoms like diarrhea, abdominal pain, and fatigue. The drug, acquired through a buyout of Celgene, did not result in a significant improvement in gastrointestinal symptoms after 12 weeks compared to a placebo. Ozanimod, approved as Zeposia for other conditions, generated sales of $434 million in 2023. Bristol Myers will analyze trial data and share results with the scientific community after AbbVie’s Rinvoq was approved for Crohn’s disease last year.
Source link
Bristol Myers’ Bowel Disease Drug Fails in Late-stage Study
